Citius Pharmaceuticals (CTXR) Stock Forecast: StockMap's 2-Week Call
CTXR stock forecast: StockMap's model leans Underperform on Citius Pharmaceuticals for the two weeks after the Nov 13 close, toward CTXR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on CTXR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Citius Pharmaceuticals last closed at $0.54, +1.89% on the session.
Against the IVW growth benchmark the position is +2.80% over the forecast window.
Citius Pharmaceuticals' market cap is $14.89M as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -45 (too close to call).
Where CTXR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 0 bullish and 15 bearish.
Agreement across those insights is 100%.
27 daily calls for CTXR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Citius Pharmaceuticals in the 15th percentile on return on equity, where 100 is best.
Citius Pharmaceuticals is classified under Health Care / Pharmaceuticals.
StockMap tracks Citius Pharmaceuticals as the 128th largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 73 Moderate Underperform, 49 Neutral and 30 Strong Underperform.
On that composite Citius Pharmaceuticals ranks 109th of 152 in the group, against a group median of -0.33.